<DOC>
	<DOCNO>NCT00258895</DOCNO>
	<brief_summary>Primary Objectives : 1 . To present safety profile 5th dose DAPTACEL® child 4 6 year age previously receive 4 dos DAPTACEL® Pentacel™ . 2 . To present pre-Dose 5 post-Dose 5 antibody response antigens DAPTACEL® child 4 6 year age previously receive 4 dos DAPTACEL® Pentacel™ . Observational Objectives : 1 . To compare equivalence criterion pre-Dose 5 post-Dose 5 antibody response antigens DAPTACEL® child 4 6 year age previously receive 4 dos DAPTACEL® Pentacel™ . 2 . To present pre-vaccination anti-poliovirus GMTs seroprotection rate . 3 . To present post-vaccination anti-poliovirus GMTs seroprotection rate among subject receive 4th dose IPV concurrently 5th dose DAPTACEL 2nd dose MMR .</brief_summary>
	<brief_title>Safety Immunogenicity DAPTACEL® 5th Dose Children 4 6 Years Old After 4 Doses Pentacel™ DAPTACEL®</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Aged ≥ 4 &lt; 7 year date birth time study vaccination Signed dated Investigational Review Board ( IRB ) approve informed consent parent legally authorize representative . Signed date IRBapproved assent subject require IRB Judged good health basis report medical history physical examination Able willing attend schedule visit comply study procedure Has document complete infant series 4th dose DAPTACEL® Pentacel™ Study P3T06 ( i.e. , 4 previous administration DAPTACEL® Pentacel™ ) . Received 5th dose DTaPcontaining vaccine . For subject DAPTACEL® arm : Received 4th dose Inactivated Poliovirus Vaccine ( IPV ) vaccine and/or 2nd dose Measles , Mumps , Rubella ( MMR ) vaccine schedule 4 6 year age . b . For subject Pentacel™ arm : Received 2nd dose MMR vaccine schedule 4 6 year age Severe hypersensitivity component vaccine anaphylactic reaction observe follow previous vaccination Serious underlie chronic disease , include , limited : ·Diabetes mellitus ; malignancy ; cardiopulmonary disease ; renal , endocrinologic , hepatic dysfunction ; hematologic disorder·Unstable evolve neurologic disorder may predispose subject seizure neurologic deterioration . These may include progressive neurologic disorder ( e.g. , infantile spasm , uncontrolled progressive encephalopathy ) encephalopathy within 7 day follow previous vaccination Known suspect primary acquire disease immune system Administration immune globulin , blood product within last 3 month , injected oral corticosteroid immunomodulator therapy within 6 week prior study vaccination . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial long receive 1 course within last 2 week prior enrollment Had allergy shot start change regimen dose allergy shot within 4 week prior study vaccination Receipt vaccine within 30 day prior study vaccination , plan receive another vaccine within 30 day Visit 2 blood draw ( applicable ) Any condition , opinion investigator , would pose health risk subject interfere evaluation vaccine Enrolled another vaccine trial Personal history physiciandiagnosed laboratoryconfirmed pertussis disease within past 30 month Known suspected allergy vaccine vaccine component intend use study .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>DAPTACEL®</keyword>
	<keyword>Pentacel™</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Whooping cough</keyword>
	<keyword>Acellular Pertussis Vaccine Adsorbed</keyword>
</DOC>